 | • レポートコード：MRC2303K107 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界の感染症治療薬市場規模が、予測期間中（2023年-2028年）、CAGR 4.3％で増大すると予測されています。本レポートでは、感染症治療薬の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患別（ヒト免疫不全ウイルス（HIV）、インフルエンザ、肝炎、結核、その他）分析、処置別（抗菌剤、抗ウィルス剤、抗寄生虫剤、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、AbbVie Inc.、Boehringer Ingelheim GmbH、Gilead Sciences, Inc.、GlaxoSmithKline plc、Janssen Pharmaceutical (Johnson & Johnson)、Merck & Co., Inc.、Novartis AG、F Hoffmann-La Roche, Ltd、Sanofi SA、Takeda Pharmaceutical Company Limited、Hookipa Pharma Inc.、Bajaj Healthcare Limitedなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の感染症治療薬市場規模：疾患別 - ヒト免疫不全ウイルス（HIV）における市場規模 - インフルエンザにおける市場規模 - 肝炎における市場規模 - 結核（TB）における市場規模 - その他疾患における市場規模 ・世界の感染症治療薬市場規模：処置別 - 抗菌剤の市場規模 - 抗ウィルス剤の市場規模 - 抗寄生虫剤の市場規模 - その他処置の市場規模 ・世界の感染症治療薬市場規模：地域別 - 北米の感染症治療薬市場規模 アメリカの感染症治療薬市場規模 カナダの感染症治療薬市場規模 メキシコの感染症治療薬市場規模 … - ヨーロッパの感染症治療薬市場規模 ドイツの感染症治療薬市場規模 イギリスの感染症治療薬市場規模 フランスの感染症治療薬市場規模 … - アジア太平洋の感染症治療薬市場規模 中国の感染症治療薬市場規模 日本の感染症治療薬市場規模 インドの感染症治療薬市場規模 … - 南米/中東の感染症治療薬市場規模 南アフリカの感染症治療薬市場規模 ブラジルの感染症治療薬市場規模 アルゼンチンの感染症治療薬市場規模 … ・競争状況 ・市場機会・将来動向 |
The infectious disease drugs market is expected to register a CAGR of 4.3% during the forecast period (2023 – 2028).
The COVID-19 outbreak has had a significant impact on the market. As employment closures have curtailed import and export activities, there has been a considerable influence on the market, resulting in shortages and unavailability of infectious drugs and supplies across healthcare facilities. Due to the temporary shutdown of production facilities, export restrictions, increased demand for the COVID-19 medication, disruptions in the supply of goods, and interruptions in services, the impact of the outbreak in its initial phase on the infectious drugs market was substantial. Additionally, clinical trials of the drug have been reduced as more and more companies delay the start of most new courses in several countries. In addition, the COVID-19 epidemic has seen a decline in outpatient services for patients with infectious diseases, which has also had a significant impact on overall market growth. For instance, according to an article published by the National Center for biotechnology information, in 2021, titled ” The impact of COVID-19 on hepatitis services and civil society organizations”, stated that the COVID-19 pandemic has affected hepatitis prevention, testing, treatment, and vaccination services globally. Similarly, as per the data published by the World Health Organization (WHO), in 2020, most malaria-endemic countries faced moderate disruptions in anti-parasitic service delivery. However, with the resumed services and procedures and the market recovering from the COVID-19, the infectious disease drugs market is expected to regain its full potential over the forecast period.
The major factors for the growth of the infectious disease drugs market are the rising awareness activities by various government and non-profit organizations, the increasing prevalence of infectious diseases, and the rising funding and increasing research and development activities. For instance, according to the data published by the World Health Organization in the Global Tuberculosis Report 2021, most of the tuberculosis cases were found in the World Health Organization (WHO) regions of South-East Asia (43%), Africa (25%) and the Western Pacific (18%), and lesser numbers of tuberculosis cases were found in Eastern Mediterranean (8.3%), the Americas (3.0%) and Europe (2.3%). Similarly, according to the World Health Organization (WHO) data published in 2021, Sub-Saharan Africa likely continues to endure the burden of malaria, accounting for approximately 95% of all cases and 96% of all deaths. Thus, rising cases of infectious diseases are expected to increase the demand for infectious drugs resulting in the high growth of the market.
However, the low penetration rates of diagnosis and treatment in developing countries and the side effects of the drugs are likely to hinder the growth of the market.
Infectious Disease Drugs Market Trends
Malaria Segment is Expected to Hold a Significant Market Share over the Forecast Period
The malaria disease segment is expected to grow over the forecast period owing to the increasing prevalence of malaria disease in developing and under-developed countries such as India, Africa, and other Southeast Asian countries, rising research and development activities by the market players as well as the health care organizations.
The rising prevalence of malaria diseases is the key factor driving the demand for infectious disease drugs over the forecast period. For instance, according to the World Health Organization (WHO) data published in 2021, Sub-Saharan Africa likely continues to endure the burden of malaria, accounting for approximately 95% of all cases and 96% of all deaths. Furthermore, as per the report “World Malaria Report” published by WHO in 2021, 29 of the 85 malaria-endemic countries accounted for 96% of all malaria cases in 2020. India contributed approximately 1.7% of malaria cases and 1.2% of deaths globally. As per the same source, there were an estimated 241 million malaria cases in 2020, as compared to 227 million cases in 2019. Thus, the increasing number of malaria cases across countries is likely to increase the demand for malarial drugs, which further increases the demand for infectious diseases, thereby increasing the market growth.
In addition, the rising research and development activities and an increasing number of company collaborations for the development of product pipelines are providing beneficial opportunities for the malarial drugs market over the forecast period. For instance, in April 2021, Janssen Pharmaceutica NV collaborated with Walter and Eliza Hall Institute of Medical Research (WEHI), an Australian Medical Research Center, to develop potential new antimalarial drug candidates. The collaborative research team discovered compounds with antimalarial activity within a collection of 80,000 drug-like molecules in the Janssen Jump-stARter Compound Library. The most promising candidates are now being further developed by the researchers towards potential antimalarial drugs.
Thus, the increasing burden of malaria disease in various countries and increasing research and development activities are likely to increase the demand for infectious disease drugs, thereby boosting the market growth.
North America is Expected to Hold Largest Market Share over the Forecast Period
North America is expected to hold a major market share in the infectious diseases drugs market owing to the rising prevalence of infectious diseases and the presence of better healthcare infrastructure, the presence of key market players, and increasing awareness programs.
The rising prevalence of infectious diseases is the key factor driving the growth of the market in the region. For instance, according to the World Health Organization, in 2021, more than 723,000 cases of malaria were reported in America in 2019, an increase of 7% as compared to 2010. Similarly, according to statistics published by MedAlertHelp, in 2022, about 5% to 20% of Americans are diagnosed with influenza every year. Further, according to the data published by the Centers for Disease Control and Prevention, in October 2021, overall, 35 million flu-related illnesses, 380,000 flu-related hospitalizations, 20,000 flu-related deaths, and 16 million flu-related medical visits were reported in the 2019-2020 season.
In addition, the increasing focus of companies and organizations on developing drugs for treating infectious diseases and rising product launches in the region is expected to boost the market growth in the United States. For instance, in September 2021, TB Alliance, a non-profit organization, granted a non-exclusive license to Lupin to manufacture the anti-TB drug pretomanid. Similarly, in March 2021, Gilead acquired Myr Pharmaceuticals for EUR 145 billion. This acquisition provides Gilead access to Hepcludex (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease in July 2020.
Thus, owing to all the above-mentioned factors, the market is expected to witness high growth over the forecast period.
Infectious Disease Drugs Market Competitor Analysis
The market studied is a fragmented market owing to the presence of various market players. Some of the market players are AbbVie Inc, Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., F Hoffmann-La Roche, Ltd, Boehringer Ingelheim GmbH, Janssen Pharmaceutical (Johnson & Johnson) and Novartis AG.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Awareness Activities by Various Government and Non-profit Organizations
4.2.2 Increasing Prevalence of Infectious Diseases
4.2.3 Rising Funding and Increasing Research and Development Activities
4.3 Market Restraints
4.3.1 Low Penetration Rates of Diagnosis and Treatment in Developing Countries
4.3.2 Side Effects of the Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Disease
5.1.1 HIV
5.1.2 Influenza
5.1.3 Hepatitis
5.1.4 Tuberculosis
5.1.5 Malaria
5.1.6 Other
5.2 By Treatment
5.2.1 Antibacterial
5.2.2 Antiviral
5.2.3 Antiparasitic
5.2.4 Other
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Boehringer Ingelheim GmbH
6.1.3 Gilead Sciences, Inc.
6.1.4 GlaxoSmithKline plc
6.1.5 Janssen Pharmaceutical (Johnson & Johnson)
6.1.6 Merck & Co., Inc.
6.1.7 Novartis AG
6.1.8 F Hoffmann-La Roche, Ltd
6.1.9 Sanofi SA
6.1.10 Takeda Pharmaceutical Company Limited
6.1.11 Hookipa Pharma Inc.
6.1.12 Bajaj Healthcare Limited
7 MARKET OPPORTUNITIES AND FUTURE TRENDS